🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

LifeStance Health Group, Inc. LFST R2KR3KPHARMA

Healthcare · Medical Care Facilities · United States
https://lifestance.com
Company Profile ↓
$12.93
+150.10% 1Y
Mkt Cap$4.92B
P/E99.46
P/B3.25
52W High$13.38
52W Low$4.81
Book Value$3.87
EPS (TTM)$0.13

Company Overview

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 11.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 46.3% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.32.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.42B (+13.9% YoY); net profit $9.66M.
  • Trailing 12 Months Year-on-year growth — revenue +26.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 46.3%, profit CAGR 11.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:46.30%
1 Year:26.10%

Compounded Profit Growth

5 Years:11.26%
1 Year:-

Stock Price Performance

1 Year:+150.10%
6 Months:+83.40%
3 Months:+18.84%
1 Month:+9.58%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 95% of range
$4.81 $13.38
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.84 · Neutral
Price Performance
1M+9.58%
3M+18.84%
6M+83.40%
1Y+150.10%
Valuation vs Sector

P/E of 99.46 is above the sector median of 25.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 46.3% over 5 years.
  • Profit CAGR of 11.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 99.5.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
99.46
Industry PE
25.45
Forward P/E
24.36
PEG Ratio
-
Book Value
$3.87
Price to Book
3.25
P/S
3.02
EV/EBITDA
37.52
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
46.30%
Profit 5Y
11.26%
Revenue (YoY)
26.10%
Earnings (YoY)
-

Profitability & Returns

ROCE
1.24%
ROE
3.43%
ROA
2.32%
Profit Margin
3.19%
Op Margin
7.25%
Gross Margin
33.56%
EPS (Latest Qtr)
$0.04
EPS (TTM)
$0.13

Balance Sheet & Liquidity

Debt/Equity
0.32
Quick Ratio
1.23
Current Ratio
1.38
Debt
$474.15M
Total Assets
$2.18B
Current Assets
$416.20M
Working Capital
$164.24M

Ownership

Promoter Holding
3.07%
Chg in Prom Hold
-0.08%
FII / Inst Holding
91.07%
Chg in FII Hold
-4.61%

Financial Snapshot

Enterprise Value
$4.92B
Total Revenue (TTM)
$1.58B
EBITDA
$135.00M
Free Cash Flow
$172.36M
Operating Cash Flow
$217.87M
Shares Outstanding
380.15M
Gross Margin
33.56%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LFST LifeStance Health Group, Inc. R2KR3KPHARMA 12.93 99.46 $4.92B 0.00% 1.24% 3.43% 46.30% 11.26%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 16.00K44.00K-1.36M----------332.97M345.31M363.81M382.19M403.48M-
Cost of Revenue --------------223.18M236.88M247.23M255.90M267.54M-
Gross Profit --------------109.79M108.43M116.58M126.30M135.93M-
Operating Expenses --------------108.19M111.38M109.17M108.21M113.65M-
Operating Income 104.00K2.69M-881.00K-47.05M-124.67M-64.85M-60.47M-38.84M-34.09M-48.41M-74.36M-16.77M-15.95M47.00K1.60M-2.95M7.41M18.08M22.28M30.65M
EBITDA --------------15.36M10.96M20.94M31.51M34.87M-
Interest Expense --------------3.07M2.90M2.81M2.88M1.79M-
Pretax Income ---------------1.47M-5.94M4.57M15.20M19.76M-
Tax Provision ---------------2.18M-2.15M3.50M3.54M5.52M-
Net Income -4.34M-3.29M-8.68M-70.03M-120.45M-62.33M-68.73M-37.85M-34.24M-45.48M-61.58M-21.10M-23.28M709.00K709.00K-3.79M1.08M11.67M14.24M23.61M
Diluted EPS --------------0.00-0.010.00-0.04-

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 212.52M1.45M859.54M1.06B1.25B1.42B
Operating Income 15.24M-286.35M-210.17M-189.13M-31.61M24.15M
Net Income 5.67M-307.20M-215.56M-186.26M-57.44M9.66M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Apr 2020May 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ----1.57B-2.17B2.11B2.12B2.20B
Current Assets ------233.22M225.73M312.51M416.20M
Cash & Equivalents ----18.83M-108.62M78.82M154.57M248.64M
Inventory ----------
Receivables ------100.87M125.41M131.80M95.71M
Total Liabilities ----536.89M-655.15M681.04M672.01M682.92M
Current Liabilities ----75.92M-176.00M202.87M228.89M251.96M
Long Term Debt ----362.53M-225.08M280.29M279.79M265.93M
Total Debt ------476.49M511.04M485.19M474.52M
Total Equity -109.10M-166.35M0-464.38M997.84M-1.52B1.43B1.45B1.52B
Shares Outstanding ------375.96M378.73M382.74M388.32M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 17.05M9.42M52.79M-16.88M107.26M146.15M
Investing Cash Flow -73.38M-194.08M-139.46M-60.34M-21.57M-36.12M
Financing Cash Flow 48.46M313.86M47.26M47.43M-9.95M-15.96M
Capital Expenditure -14.31M-94.49M-79.25M-40.52M-21.57M-36.12M
Free Cash Flow 2.73M-85.07M-26.47M-57.40M85.69M110.03M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------
Operating Margin % 7.2%-19,816.8%-24.5%-17.9%-2.5%1.7%
Net Margin % 2.7%-21,259.3%-25.1%-17.6%-4.6%0.7%
ROE % -3.4%--14.2%-13.0%-4.0%0.6%
ROCE % ---10.5%-9.9%-1.7%1.2%

Shareholding Pattern

Insiders
3.07%
Institutions
91.07%
Public Float
93.96%

Top Institutional Holders

#Holder% HeldSharesValue
1 TPG GP A, LLC 29.24% 111.74M $1.39B
2 FMR, LLC 15.24% 58.25M $723.50M
3 Blackrock Inc. 9.51% 36.35M $451.45M
4 Summit Partners, L.P. 6.10% 23.31M $289.51M
5 Vanguard Portfolio Management LLC 3.65% 13.96M $173.39M
6 Jennison Associates LLC 3.16% 12.08M $150.00M
7 Dimensional Fund Advisors LP 2.99% 11.43M $141.93M
8 Vanguard Capital Management LLC 2.55% 9.74M $120.91M
9 State Street Corporation 2.15% 8.23M $102.20M
10 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1.56% 5.95M $73.87M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LFST

Google News Fri, 23 Oct 2026

LifeStance Health Group, Inc. Estimates – NASDAQ:LFST - TradingView

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBvVWRfUGZrT3o1NzZESWJ1bkFudWRfTG9KU19ZX2ZfU2hQUzYybkRhSGJSd3ZzZFJfUnpnTklMNzZDUXlpTHlvalhxRGJpZl9oZGpKTkNkNG40bE9WVm5FMlpPemt5a1Ffc0NXZGtNMmxCam9lMHFaQQ?oc=5" target="_blank">LifeS…

Google News hu, 22 Oct 2026

LifeStance Health Group, Inc. (LFST) Stock Forecasts - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOQXZuN05neW02MmFMV1RtazVpdDR3bVZubUdrZU82XzBKWTh0SnhxQXBmOVVlejU1cHp3RS1XTE4wWmxkUVVpOWwxMlR5WVZwRzJCM3p3cm5CTjE4VURVZHZwQVZkdFE2bTJfc3Z4M3ktZ251bVk2V3Q3eXliR0t4VGFMU1k1VVFhZ1JFV2…

Google News Mon, 28 Sep 2026

What’s Going On With LifeStance Health Group (LFST)? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPd3ZPOVFJcVJVbmZydVB3UFhqcnMwbFRIb1JqcVo0SHdGSjhIRlVSamZ5S1NRTGt4TjJGcEU5dmRpbWdCWnR4WmlVbzVWREtRWmJlNmRaRmVDLUVRbExjQUo2QkRyX29WXzVva3ZfUHRZUS1IeUNzQ3llRmhsTnE3empaLVdvRzhoLXJBMn…

Google News Fri, 23 Oct 2026

LFST Mar 2027 16.000 call (LFST270319C00016000) stock historical prices and data - Yahoo Finance Singapore

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE04MVlwRzl3VTZkUm5PUEdfUlhUUnBtUU1UR1dwekc0TXVyZnh6cWR5cDhFc3Naa2kxa2ZnZnNoWGFyWVRRRlZxdW5LTjR6N25nOXB1Z1pvc2t1a1BNLV95MXR3Y1hXcWZadGRXdXpRb1c?oc=5" target="_blank">LFST Mar 2027 16…

Google News hu, 22 Oct 2026

LifeStance Health Group, Inc. (LFST) Stock forecasts - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNUnZtLVNYaktKdjZESFpkYWhwMzZJWVRReTZZeEtYYmszRnZDMldpZGdhUTZ3YzQtVWxMd1BpdEtUd2dTVFRJdlRjMUVGQnVLYVo1NXpLTVo4a1NLanZCNDNNdTNRbmpsZFJFVzJyZHNxTzhtYV9WVmgzdjZGTzdydEM3OGJBTmRpeGxYUl…

Google News Fri, 23 Oct 2026

LFST Mar 2027 3.000 call (LFST270319C00003000) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE4wWk1SUnBDNVZZRDNJUVROMDFhOVotcXlxLTBzM2drOXIyQms1emNSUEtGbU5qdy1jYUhsZGc4SFY4V09qUlpTQWRfSkFGbzVfaFNzRGpiM056cVUxMmtNbVlYR1JMenE5ME01bi1xNU4?oc=5" target="_blank">LFST Mar 2027 3.…

LFST — Frequently Asked Questions

What is the current share price of LifeStance Health Group, Inc. (LFST)?

As of 2026-10-23 16:27 PDT, LifeStance Health Group, Inc. (LFST) trades at $12.93 on NasdaqGS. Its 52-week range is $4.81 to $13.38.

What is the market capitalisation of LFST?

LifeStance Health Group, Inc. (LFST) has a market capitalisation of $4.92B on NasdaqGS.

What is the P/E ratio of LFST?

LFST trades at a trailing price-to-earnings (P/E) ratio of 99.46. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 3.25.

What is the return on equity (ROE) of LFST?

LFST has a return on equity (ROE) of 3.43%. Its return on capital employed (ROCE) is 1.24%.

Is LFST a good stock to buy?

This page provides a data-driven analysis of LifeStance Health Group, Inc. (LFST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space